ABSTRACT
The increasing prevalence of multidrug-resistant tuberculosis (MDR-TB) has exacerbated the ongoing public 3 health challenge of tuberculosis control. 1 In spite of significant increases in the detection of MDR-TB in recent 4 years, global control efforts are still limited by insufficient laboratory testing capacity; in 2013, only 28% of the 5 480,000 estimated incident MDR-TB cases were diagnosed worldwide. 2 Improvements in screening methods to 6 identify the patients most at-risk of MDR-TB may help to increase testing efficiency and reduce time to 7 diagnosis of MDR-TB cases. Better and faster diagnosis, combined with initiation on appropriate treatment, will 8 also help to reduce disease transmission.
10
Previous TB treatment is the most significant known risk factor for MDR-TB, and the prevalence of MDR-TB 11 also varies significantly by geographical region. 3 The development of drug resistance by drug selection pressure 12 may be related to several factors, including drug supply and quality of care. 4 In addition, a significant amount of 13 evidence now indicates that both patient and bacteria-specific variables are important contributors to the 14 development of drug resistance.
5-8 15
Genetically-based drug resistance in Mycobacterium tuberculosis occurs exclusively as a result of chromosomal 16 mutations, and recent studies indicate that the rate at which these bacteria acquire drug-resistant mutations may 17 be much higher than previously estimated. [9] [10] [11] [12] Importantly, models developed to predict the evolution of MDR-
18
TB in vivo reveal that patients with higher bacterial burdens, who have correspondingly more potential for drug-19 resistant mutations to be present, are at greater risk to develop MDR-TB than patients who have lower bacterial 20 burdens.
9,10 21
Clinically, more severe pulmonary tuberculosis disease is characterized by an increase in the amount of lung area 22 involved, density of lesions, and cavitation apparent on chest x-ray, which is associated with higher rates of 23 smear-positivity for acid-fast bacilli 13 and reduced time to detection in culture. 14 
24
By integrating the prediction that patients with higher bacterial burdens are more likely to develop MDR-TB, 25 with evidence that pulmonary TB patients with more severe disease produce larger numbers of bacteria in their 26 sputum, we aimed to determine whether patients with higher sputum bacterial loads are more likely to be MDR-
27
TB cases. We assessed this using a case-control study of archival data from a TB reference laboratory in
28
Cameroon.
30

STUDY POPULATION AND METHODS
32
Study population and setting
33
The study population consisted of patients from whom sputum specimens were received at the Tuberculosis
34
Reference Laboratory Bamenda in Cameroon for drug susceptibility testing (DST 
45
This was an unmatched case control study of archived routine laboratory data. Two case definitions were used.
46
In the main analysis, case patients were defined as those with TB bacilli resistant to both isoniazid and rifampin, and control patients were those with TB bacilli susceptible to both or monoresistant to one of the drugs. guidelines, any specimen with any resistance on the rapid assay was also tested using the proportion method on were used for all analyses. The STROBE recommendations were followed for reporting these data. 
95
In the multivariable analysis of 80 cases and 521 controls ( and MDR-TB since cavitary pulmonary TB is associated with higher sputum bacterial load. 29, 30 This work was motivated by predictions that higher patient bacterial load is associated with multidrug 132 resistance 9,10 and evidence that higher patient bacterial load corresponds to higher sputum bacterial load. Among all retreatment patients tested, 26% had a smear microscopy grade of ≤1+, 23% were graded as 2+, and 51% as 3+. (C) Among patients identified as MDR-TB cases, 4% had a smear microscopy grade of ≤1+, 21% as 2+, and 75% as 3+. An association between higher smear microscopy grade and MDR-TB was observed for retreatment patients with different treatment histories, including those classified as failure of treatment, as well as those classified as relapse or return after default and who were not on treatment at baseline diagnosis.
